Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.52 |
| ▸ | CALML3 | P27482 | 7/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790221 | 0.90 | CALML3 (0.56) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL18770280 | 0.90 | CALML3 (0.56) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL18786422 | 0.88 | CALML3 (0.49) | MAOACALML3F10MAOBLMNA | |
| SCHEMBL1393478 | 0.87 | MAOA (0.65) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6093515 | 0.83 | CALML3 (0.63) | MAOACALML3MAOB | |
| SCHEMBL18786530 | 0.83 | CALML3 (0.63) | MAOACALML3MAOB | |
| SCHEMBL18790181 | 0.82 | CALML3 (0.62) | MAOACALML3MAOB | |
| SCHEMBL14763265 | 0.81 | MAOA (0.66) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL3080500 | 0.81 | MAOA (0.66) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL4573584 | 0.80 | MAOA (0.63) | MAOACALML3F10MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947205-B2 | Oxazolidinone compounds and methods of use thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210061777-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20190248753-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2019-08-15 | — | — | US | disclosed |
| US-20180290987-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2018-10-11 | — | — | US | disclosed |
| EP-3364968-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070024-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947205-B2 | Oxazolidinone compounds and methods of use thereof as antibacterial agents | OXA1L, ERAL1, TBCD | MAOA 1773/4885CALML3 3904/4885F10 3953/4885 |
| US-20190248753-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, ERAL1, TBCD | MAOA 1773/4885CALML3 3904/4885F10 3953/4885 |
| US-20180290987-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, ERAL1, TBCD | MAOA 1773/4885CALML3 3904/4885F10 3953/4885 |
| US-20210061777-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, ERAL1, TBCD | MAOA 1773/4885CALML3 3904/4885F10 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.